(Q43941683)

28 November 2017

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses (English)

1 reference

28 November 2017

1 reference

5

Deisboeck TS

1 reference

28 November 2017

Ikeda K

1

1 reference

28 November 2017

Ichikawa T

2

1 reference

28 November 2017

Wakimoto H

3

1 reference

28 November 2017

Silver JS

4

1 reference

28 November 2017

Finkelstein D

6

1 reference

28 November 2017

Harsh GR 4th

7

1 reference

28 November 2017

Louis DN

8

1 reference

28 November 2017

Bartus RT

9

1 reference

28 November 2017

Hochberg FH

10

1 reference

28 November 2017

Chiocca EA

11

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 August 1999

1 reference

28 November 2017

1 reference

28 November 2017

5

1 reference

28 November 2017

881-887

1 reference

28 November 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/11320

28 November 2017

0 references

cites work

A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer

1 reference

7 January 2021

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

1 reference

7 January 2021

In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2.

1 reference

7 January 2021

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

1 reference

7 January 2021

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas

1 reference

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

7 January 2021

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors.

1 reference

7 January 2021

Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.

1 reference

7 January 2021

Reovirus therapy of tumors with activated Ras pathway

1 reference

7 January 2021

Therapeutic replication-competent herpes virus

1 reference

7 January 2021

Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms.

1 reference

7 January 2021

Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7.

1 reference

7 January 2021

Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector

1 reference

7 January 2021

Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses.

1 reference

7 January 2021

Neoglycolipids as probes of oligosaccharide recognition by recombinant and natural mannose-binding proteins of the rat and man.

1 reference

7 January 2021

Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy.

1 reference

7 January 2021

Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas

1 reference

7 January 2021

Intravenous RMP-7 increases delivery of ganciclovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy

1 reference

7 January 2021

Cerebrovascular effects of the bradykinin analog RMP-7 in normal and irradiated dog brain

1 reference

7 January 2021

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

1 reference

7 January 2021

T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses.

1 reference

7 January 2021

A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody

1 reference

7 January 2021

Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase.

1 reference

7 January 2021

In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor.

1 reference

7 January 2021

Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo

1 reference

7 January 2021

Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant

1 reference

7 January 2021

Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant

1 reference

7 January 2021

Preparation of herpes simplex virus of high titer.

1 reference

7 January 2021

Lineage-independent determination of cell type in the embryonic mouse retina

1 reference

7 January 2021

Identifiers

DOI

10.1038/11320

1 reference

28 November 2017

1 reference